Literature DB >> 7693975

Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.

L Stewart1, V M Vogt.   

Abstract

Protease (PR)-defective avian leukosis virus particles display 300-fold-reduced levels of reverse transcriptase (RT) activity relative to wild-type particles. This observation suggests that during virion assembly RT is activated by proteolytic maturation of the Gag-Pol polyprotein precursor. To study the relationship between proteolytic cleavage and RT activation, we subjected PR-defective virion cores to digestion with purified viral PR and analyzed the structure of the major polypeptides produced as well as RT activity. Under conditions in which Gag precursors were fully matured, the RT domain was only incompletely released from the Gag-Pol precursor, remaining tethered to the upstream Gag domains PR or NC-PR. In the same reaction, RT activity was stimulated only three-fold, or 100-fold less than expected for a fully active RT. The poor activation suggested that the NC or PR domains could repress RT activity. To test this idea, we constructed recombinant baculoviruses expressing 19 different fusion proteins with upstream Gag or downstream Pol sequences attached to RT. Each protein was partially purified and assayed for its inherent RT activity. The results are consistent with the idea that Gag sequences can inhibit RT activity but indicate that the size of the Pol domain as well as the status of the PR domain (wild-type or mutant) also can profoundly influence activity. Several of the constructed Gag-Pol fusion proteins contained a wild-type PR domain. Some of these underwent intracellular PR-mediated processing, while others did not. All proteins in which the PR domain was preceded by upstream Gag sequences showed specific proteolysis. By contrast, all proteins initiated with a methionine placed one residue upstream of the natural N terminus of PR failed to show specific proteolysis. Amino-terminal sequencing of one such protein yielded the correct amino acid sequence and showed that the initiating methionine was not removed. One interpretation of these findings is that activation of PR requires the generation of the precise N terminus of the mature PR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693975      PMCID: PMC238225     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis.

Authors:  Z Hostomsky; Z Hostomska; T B Fu; J Taylor
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

2.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

3.  Amino acid sequence analysis of reverse transcriptase subunits from avian myeloblastosis virus.

Authors:  T D Copeland; D P Grandgenett; S Oroszlan
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

4.  RNA-dependent DNA polymerase of avian sarcoma virus B77. II. Comparison of the catalytic properties of the alpha, beta2, and alphabeta enzyme forms.

Authors:  A Hizi; J P Leis; W K Joklik
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

5.  RNA-dependent DNA polymerase of avian sarcoma virus B77. I. Isolation and partial characterization of the alpha, beta2, and alphabeta forms of the enzyme.

Authors:  A Hizi; W K Joklik
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

6.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

7.  Quantitation of avian RNA tumor virus reverse transcriptase by radioimmunoassay.

Authors:  A Panet; D Baltimore; T Hanafusa
Journal:  J Virol       Date:  1975-07       Impact factor: 5.103

8.  Synthesis and processing of polymerase proteins of wild-type and mutant avian retroviruses.

Authors:  R N Eisenman; W S Mason; M Linial
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

9.  Effect of p15-associated protease from an avian RNA tumor virus on avian virus-specific polyprotein precursors.

Authors:  K Moelling; A Scott; K E Dittmar; M Owada
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

10.  Endonuclease activity of purified RNA-directed DNA polymerase from avian myeloblastosis virus.

Authors:  M Golomb; D P Grandgenett
Journal:  J Biol Chem       Date:  1979-03-10       Impact factor: 5.157

View more
  5 in total

1.  Analysis of cleavage site mutations between the NC and PR Gag domains of Rous sarcoma virus.

Authors:  G Schatz; I Pichova; V M Vogt
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

2.  Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function.

Authors:  G W Schatz; J Reinking; J Zippin; L K Nicholson; V M Vogt
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.

Authors:  Steve C Pettit; Jeffrey N Lindquist; Andrew H Kaplan; Ronald Swanstrom
Journal:  Retrovirology       Date:  2005-11-01       Impact factor: 4.602

4.  Nucleocapsid mutations turn HIV-1 into a DNA-containing virus.

Authors:  Laurent Houzet; Zakia Morichaud; Ludovic Didierlaurent; Delphine Muriaux; Jean-Luc Darlix; Marylène Mougel
Journal:  Nucleic Acids Res       Date:  2008-02-22       Impact factor: 16.971

5.  The conserved N-terminal basic residues and zinc-finger motifs of HIV-1 nucleocapsid restrict the viral cDNA synthesis during virus formation and maturation.

Authors:  Ludovic Didierlaurent; Laurent Houzet; Zakia Morichaud; Jean-Luc Darlix; Marylène Mougel
Journal:  Nucleic Acids Res       Date:  2008-07-18       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.